ALK and cancer: In general, recommended treatment for patients include targeted therapies for patients with advanced NSCLC (aNSCLC) bearing alterations in driver oncogenes (EGFR, ALK, ROS1, BRAF, NTRK, RET, or MET), cancer immunotherapy (CIT) with immune checkpoint inhibitors alone or in combination with chemotherapy [3].